Resistant Dermatomyositis Improves Quickly, Significantly With Combination Drug

(MedPage Today) — DENVER — Treatment-resistant dermatomyositis improved significantly with the investigational TYK2/JAK1 inhibitor brepocitinib, according to a randomized trial.
The higher of two doses of brepocitinib improved the total dermatomyositis…